Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Britain Courts Anthropic Amid US Defense Department Dispute 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2016 -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, announced today that it has joined over 80 pharmaceutical, biotechnology, and diagnostics companies in drafting and signing the Declaration on Combating Antimicrobial Resistance. The Declaration – which highlights the continued increase of bacterial resistance to antibiotics and the urgent need to develop new, innovative drugs – is a call to action, outlining specific initiatives that governments and industry can implement in a collaborative effort to further address the threat of Antimicrobial Resistance (AMR). This initiative further demonstrates Achaogen’s commitment to economic, regulatory, and reimbursement reform toward establishing a sustainable solution that incentivizes the development and commercialization of novel antibiotics addressing the unmet need of treating drug resistant infections.
“Achaogen is focused on the discovery and development of new antibacterials to treat multi-drug resistant, gram-negative infections and is committed to participating in the coordinated global action required to address the public health threat posed by AMR,” said Kenneth Hillan, Achaogen’s Chief Executive Officer. “We applaud the efforts of Lord O’Neill’s Review on AMR and are pleased to support this Declaration and the call for collective global measures to overcome the barriers to the development and commercialization of life-saving antibiotics.”
The Declaration, along with a complete list of signatories, is available at the Review on AMR website at www.amr-review.org/industry-declaration.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious urinary tract, lung, and bloodstream infections due to Enterobacteriaceae, including CRE. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
Contact Candice Knoll Blueprint Life Science Group 415.375.3340 Ext. 4 [email protected]
